Preparation of Co-Amorphous Levofloxacin Systems for Pulmonary Application
Preparation of Co-Amorphous Levofloxacin Systems for Pulmonary Application
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Addressing antimicrobial resistance requires new approaches in various disciplines of pharmaceutical sciences. The fluoroquinolone levofloxacin (LEV) plays an important role in the therapy of lung infections. However, its effectiveness is limited by its severe side effects involving tendinopathy, muscle weakness and psychiatric disturbance. Therefo...
Alternative Titles
Full title
Preparation of Co-Amorphous Levofloxacin Systems for Pulmonary Application
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_55203d12395b4e18ac4aaade47991094
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_55203d12395b4e18ac4aaade47991094
Other Identifiers
ISSN
1999-4923
E-ISSN
1999-4923
DOI
10.3390/pharmaceutics15061574
